OA02.05 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study

Sugemalimab is a full-length, fully human IgG4 monoclonal antibody targeting PD-L1. GEMSTONE-301 is an ongoing phase 3 trial to evaluate sugemalimab as a consolidation treatment in patients(pts) with stage III NSCLC without disease progression following chemoradiotherapy (CRT). This is the first phase 3 trial in this setting to include pts who received either concurrent or sequential chemoradiotherapy (cCRT or sCRT). In the PFS interim analysis, sugemalimab showed a statistically significant and clinically meaningful improvement in PFS compared with placebo.